Embark Veterinary Company Profile

Background

Overview

Embark Veterinary, Inc., founded in 2015, is a biotechnology company specializing in canine genomics and health. Headquartered in Boston, Massachusetts, Embark offers comprehensive dog DNA testing services to pet owners, breeders, and veterinarians, aiming to enhance canine health through genetic insights.

Mission and Vision

Embark's mission is to end preventable disease in dogs by providing detailed genetic information that empowers pet owners and veterinarians to make informed health decisions. The company envisions a future where every dog has access to personalized care based on their unique genetic makeup.

Primary Area of Focus

Embark focuses on canine genetics, offering DNA tests that analyze over 200,000 genetic markers to provide insights into breed identification, ancestry, and health risks. This extensive analysis aids in the early detection of genetic conditions, promoting proactive health management for dogs.

Industry Significance

As a leader in canine genomics, Embark has significantly advanced the understanding of dog genetics, contributing to improved health outcomes and the development of breed-specific health strategies. Its partnership with Cornell University College of Veterinary Medicine underscores its commitment to scientific research and innovation in the field.

Key Strategic Focus

Core Objectives

Genetic Research and Discovery: Embark aims to identify genetic markers associated with various canine health conditions, facilitating early detection and prevention.

Customer Education: The company is dedicated to educating pet owners and veterinarians about the importance of genetic testing in canine health management.

Product Development: Embark continually refines its DNA testing services to provide the most accurate and comprehensive genetic information available.

Specific Areas of Specialization

Breed Identification: Offering detailed insights into a dog's breed composition, aiding in understanding behavior, health predispositions, and care requirements.

Health Screening: Providing tests for over 230 genetic health conditions, enabling proactive health management and informed breeding decisions.

Key Technologies Utilized

Research-Grade DNA Genotyping: Embark employs a DNA genotyping platform that analyzes over 200,000 genetic markers, ensuring high accuracy in test results.

Data Analytics: Utilizing advanced data analytics to interpret genetic information, providing actionable insights for canine health.

Primary Markets Targeted

Pet Owners: Individuals seeking to understand their dog's genetic background and health risks.

Veterinarians: Professionals integrating genetic information into their practice for enhanced health diagnostics and management.

Breeders: Those aiming to make informed breeding decisions to promote healthier dog populations.

Financials and Funding

Funding History

Seed Funding: In 2015, Embark secured $1.6 million in seed funding to support its initial research and development efforts.

Series A Funding: In April 2019, the company raised $10 million in Series A funding, led by F-Prime Capital, to expand its genetic database and enhance testing capabilities.

Series B Funding: In July 2021, Embark raised $75 million in Series B funding, led by SoftBank Vision Fund 2, valuing the company at $700 million. This funding aimed to support key hires and further strengthen its canine genetics database.

Total Funds Raised

Embark has raised a total of $86.6 million across its funding rounds, supporting its growth and technological advancements.

Notable Investors

F-Prime Capital: Participated in the Series A funding round, contributing to the company's expansion efforts.

SoftBank Vision Fund 2: Led the Series B funding round, significantly boosting Embark's valuation and resources.

Utilization of Capital

The funds have been utilized for:

Research and Development: Enhancing genetic testing technologies and expanding the genetic database.

Hiring: Recruiting key personnel to support growth and innovation.

Marketing and Outreach: Increasing brand awareness and educating the public on the importance of canine genetic testing.

Pipeline Development

Key Pipeline Candidates

Embark's pipeline focuses on:

Genetic Health Tests: Developing tests for additional genetic conditions to provide comprehensive health screenings.

Breed Identification Enhancements: Improving the accuracy and range of breed identification services.

Stages of Development

Embark's products are in various stages, from research and development to market-ready services, continually evolving to incorporate the latest scientific findings.

Target Conditions

The company targets a wide array of genetic health conditions, including but not limited to:

Hip Dysplasia: A common skeletal condition in dogs.

Progressive Retinal Atrophy: A group of genetic diseases that cause retinal degeneration.

Degenerative Myelopathy: A progressive disease of the spinal cord.

Anticipated Milestones

Database Expansion: Continuing to grow the genetic database to enhance test accuracy.

Product Launches: Introducing new health tests and breed identification services.

Scientific Publications: Publishing research findings to contribute to the scientific community.

Technological Platform and Innovation

Proprietary Technologies

Embark Genotyping Platform: A research-grade DNA genotyping platform analyzing over 200,000 genetic markers, providing high-resolution genetic information.

Significant Scientific Methods

Crowdsourced Genetic Research: Utilizing data from pet owners to identify genetic markers associated with traits and health conditions.

Genetic Association Studies: Conducting studies to link specific genetic variants to health traits, such as the identification of the gene responsible for blue eyes in Siberian Huskies.

Leadership Team

Key Executives

Ryan Boyko: Co-founder and CEO. Ryan has a background in genetics and has been instrumental in developing Embark's scientific approach.

Adam Boyko: Co-founder and Chief Science Officer. Adam's expertise in canine genetics has been pivotal in shaping the company's research initiatives.

Matt Salzberg: Co-founder and Board Member. Matt brings experience from his previous role as CEO of Blue Apron, contributing to Embark's strategic direction.

Competitor Profile

Market Insights and Dynamics

The canine genetic testing market is expanding, driven by increasing awareness of genetic health's role in pet care. Pet owners are seeking proactive health management solutions, creating opportunities for companies like Embark to lead in this space.

Competitor Analysis

Wisdom Panel: Offers genetic testing services for dogs, focusing on breed identification and health screening.

DNA My Dog: Provides DNA testing services with a focus on breed identification.

Orivet: Offers genetic testing and personalized health plans for dogs.

Strategic Collaborations and Partnerships

Cornell University College of Veterinary Medicine: Embark collaborates with Cornell to advance canine genetic research and enhance testing accuracy.

Operational Insights

Embark differentiates itself through its extensive genetic database and research-grade testing platform, offering more comprehensive and accurate results compared to competitors.

Strategic Opportunities and Future Directions